Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Adolescent
Adult
Antimalarials
/ therapeutic use
Artemisinins
/ therapeutic use
Cambodia
/ epidemiology
Child
Female
Humans
Malaria, Falciparum
/ drug therapy
Malaria, Vivax
/ drug therapy
Male
Mass Drug Administration
Myanmar
/ epidemiology
Prevalence
Primaquine
/ therapeutic use
Quinolines
/ therapeutic use
Recurrence
Treatment Outcome
Vietnam
/ epidemiology
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
06
2019
accepted:
08
01
2020
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Mass administrations of antimalarial drugs (MDA) have reduced the incidence and prevalence of P. falciparum infections in a trial in the Greater Mekong Subregion. Here we assess the impact of the MDA on P. vivax infections. Between May 2013 and July 2017, four villages in each Myanmar, Vietnam, Cambodia and Lao PDR were selected based on high prevalence of P. falciparum infections. Eight of the 16 villages were randomly assigned to receive MDA consisting of three-monthly rounds of three-day courses of dihydroartemisinin-piperaquine and, except in Cambodia, a single low-dose of primaquine. Cross-sectional surveys were conducted at quarterly intervals to detect Plasmodium infections using ultrasensitive qPCR. The difference in the cumulative incidence between the groups was assessed through a discrete time survival approach, the difference in prevalence through a difference-in-difference analysis, and the difference in the number of participants with a recurrence of P. vivax infection through a mixed-effect logistic regression. 3,790 (86%) residents in the intervention villages participated in at least one MDA round, of whom 2,520 (57%) participated in three rounds. The prevalence of P. vivax infections fell from 9.31% to 0.89% at month 3 but rebounded by six months to 5.81%. There was no evidence that the intervention reduced the cumulative incidence of P.vivax infections (95% confidence interval [CI] Odds ratio (OR): 0.29 to 1.36). Similarly, there was no evidence of MDA related reduction in the number of participants with at least one recurrent infection (OR: 0.34; 95% CI: 0.08 to 1.42). MDA with schizontocidal drugs had a lasting effect on P. falciparum infections but only a transient effect on the prevalence of P. vivax infections. Radical cure with an 8-aminoquinoline will be needed for the rapid elimination of vivax malaria.
Sections du résumé
BACKGROUND
Mass administrations of antimalarial drugs (MDA) have reduced the incidence and prevalence of P. falciparum infections in a trial in the Greater Mekong Subregion. Here we assess the impact of the MDA on P. vivax infections.
METHODS
Between May 2013 and July 2017, four villages in each Myanmar, Vietnam, Cambodia and Lao PDR were selected based on high prevalence of P. falciparum infections. Eight of the 16 villages were randomly assigned to receive MDA consisting of three-monthly rounds of three-day courses of dihydroartemisinin-piperaquine and, except in Cambodia, a single low-dose of primaquine. Cross-sectional surveys were conducted at quarterly intervals to detect Plasmodium infections using ultrasensitive qPCR. The difference in the cumulative incidence between the groups was assessed through a discrete time survival approach, the difference in prevalence through a difference-in-difference analysis, and the difference in the number of participants with a recurrence of P. vivax infection through a mixed-effect logistic regression.
RESULTS
3,790 (86%) residents in the intervention villages participated in at least one MDA round, of whom 2,520 (57%) participated in three rounds. The prevalence of P. vivax infections fell from 9.31% to 0.89% at month 3 but rebounded by six months to 5.81%. There was no evidence that the intervention reduced the cumulative incidence of P.vivax infections (95% confidence interval [CI] Odds ratio (OR): 0.29 to 1.36). Similarly, there was no evidence of MDA related reduction in the number of participants with at least one recurrent infection (OR: 0.34; 95% CI: 0.08 to 1.42).
CONCLUSION
MDA with schizontocidal drugs had a lasting effect on P. falciparum infections but only a transient effect on the prevalence of P. vivax infections. Radical cure with an 8-aminoquinoline will be needed for the rapid elimination of vivax malaria.
Identifiants
pubmed: 32023293
doi: 10.1371/journal.pone.0228190
pii: PONE-D-19-17594
pmc: PMC7001954
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Primaquine
MVR3634GX1
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0228190Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101148/Z/13/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
We declare no competing of interests in any form related to employment, consultancy, patents, products in development, or marketed product, etc. None of our authors is affiliated with a commercial entity.
Références
Am J Trop Med Hyg. 2019 Jan;100(1):213-221
pubmed: 30350771
Malar J. 2011 Oct 11;10:297
pubmed: 21989376
Glob Health Action. 2017;10(1):1366136
pubmed: 28914184
Lancet. 1983 Aug 27;2(8348):500-3
pubmed: 6136655
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
J Infect Dis. 2019 Apr 16;219(9):1499-1509
pubmed: 30500927
Malar J. 2016 Sep 27;15(1):494
pubmed: 27677694
PLoS Med. 2019 Feb 15;16(2):e1002745
pubmed: 30768615
Malar J. 2017 Jan 6;16(1):17
pubmed: 28061908
Ann N Y Acad Sci. 2015 Apr;1342:62-7
pubmed: 25891142
Malar J. 2010 Apr 21;9:105
pubmed: 20409302
Malar J. 2014 Feb 07;13:51
pubmed: 24502194
Lancet Infect Dis. 2018 May;18(5):565-572
pubmed: 29398388
PLoS One. 2013 Dec 03;8(12):e78819
pubmed: 24312446
Malar J. 2018 Nov 3;17(1):405
pubmed: 30390647
J Clin Microbiol. 2014 Sep;52(9):3303-9
pubmed: 24989601
Malar J. 2017 Feb 14;16(1):75
pubmed: 28196536
Malar J. 2018 Jan 27;17(1):53
pubmed: 29374462
Am J Trop Med Hyg. 2008 Sep;79(3):378-84
pubmed: 18784229
Malar J. 2017 Sep 11;16(1):361
pubmed: 28893237
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87
pubmed: 18165478
Malar J. 2019 Dec 18;18(1):428
pubmed: 31852499
Malar J. 2009 Sep 14;8:212
pubmed: 19747403
Parasit Vectors. 2013 Apr 18;6:109
pubmed: 23597046
Malar J. 2013 Nov 01;12:383
pubmed: 24175930
Stat Med. 2015 Dec 10;34(28):3637-47
pubmed: 26239405
Wellcome Open Res. 2017 Sep 6;2:81
pubmed: 29062913
Clin Infect Dis. 2019 Apr 8;68(8):1311-1319
pubmed: 30952158